{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:43:14Z","timestamp":1775119394979,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.tiv.2008.11.010","type":"journal-article","created":{"date-parts":[[2008,12,10]],"date-time":"2008-12-10T15:59:28Z","timestamp":1228924768000},"page":"217-226","source":"Crossref","is-referenced-by-count":29,"title":["A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase"],"prefix":"10.1016","volume":"23","author":[{"given":"Mesens","family":"Natalie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steemans","family":"Margino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hansen","family":"Erik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peters","family":"Annelieke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verheyen","family":"Geert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanparys","family":"Philippe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tiv.2008.11.010_bib1","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1016\/j.febslet.2006.08.061","article-title":"Drug-induced phospholipidosis","volume":"580","author":"Anderson","year":"2006","journal-title":"FEBS Letters"},{"key":"10.1016\/j.tiv.2008.11.010_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/toxsci\/kfl184","article-title":"Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells","volume":"96","author":"Atienzar","year":"2007","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.tiv.2008.11.010_bib3","first-page":"6931","article-title":"Carcinogenicity studies of fluoxetine hydrochloride in rats and mice","volume":"52","author":"Bendele","year":"1992","journal-title":"Cancer Research"},{"key":"10.1016\/j.tiv.2008.11.010_bib4","first-page":"564","article-title":"Introduction of a high-resolution cytochemical method for studying the distribution of phospholipids in biological tissues","volume":"46","author":"Coulombe","year":"1988","journal-title":"European Journal of Cell Biology"},{"key":"10.1016\/j.tiv.2008.11.010_bib5","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0014-4835(77)90120-8","article-title":"Lens opacities associated with lipidosis-like ultrastructural alterations in rats treated with chloroquine, chlorphentermine or iprindole","volume":"24","author":"Drenckhahn","year":"1977","journal-title":"Experimental Eye Research"},{"key":"10.1016\/j.tiv.2008.11.010_bib6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF00498524","article-title":"Adrenocortical function of rats under prolonged administration of lipidosis-inducing drugs","volume":"321","author":"Duncker","year":"1982","journal-title":"Archives of Pharmacology"},{"key":"10.1016\/j.tiv.2008.11.010_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.etp.2007.01.004","article-title":"Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development","volume":"58","author":"Fujimura","year":"2007","journal-title":"Experimental and Toxicological Pathology: Official Journal of the Gesellschaft f\u00fcr Toxikologische Pathologie"},{"key":"10.1016\/j.tiv.2008.11.010_bib8","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1378\/chest.107.6.1763","article-title":"Fluoxetine hydrochloride (Prozac)-induced pulmonary disease","volume":"107","author":"Gonzalez-Rothi","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.tiv.2008.11.010_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/tx600260a","article-title":"Applying mechanisms of chemical toxicity to predict drug safety","volume":"20","author":"Guengerich","year":"2007","journal-title":"Chemical Research in Toxicology"},{"key":"10.1016\/j.tiv.2008.11.010_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/019262339702500111","article-title":"Cationic amphiphilic drug-induced phospholipidosis","volume":"25","author":"Halliwell","year":"1997","journal-title":"Toxicological Pathology"},{"key":"10.1016\/j.tiv.2008.11.010_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jat.1120","article-title":"A clinical flow cytometric biomarker strategy: validation of peripheral leukocyte phospholipidosis using Nile Red","volume":"26","author":"Halstead","year":"2006","journal-title":"Journal of Applied Toxicology"},{"key":"10.1016\/j.tiv.2008.11.010_bib12","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3109\/00498259009046842","article-title":"Human accumulation potential of xenobiotics: potential of catamphiphilic drugs to promote their accumulation via inducing lipidosis or mucopolysaccharidosis","volume":"20","author":"Hein","year":"1990","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tiv.2008.11.010_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00341016","article-title":"Lipidosis-like alterations in cultured macrophages exposed to local anaesthetics","volume":"55","author":"J\u00e4gel","year":"1984","journal-title":"Archives of Toxicology"},{"key":"10.1016\/j.tiv.2008.11.010_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/toxsci\/kfj067","article-title":"Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential","volume":"90","author":"Kasahara","year":"2006","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.tiv.2008.11.010_bib15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0031-6997(25)00049-3","article-title":"Cationic amphiphilic drugs and phospholipid storage disorder","volume":"42","author":"Kodavanti","year":"1990","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.tiv.2008.11.010_bib16","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrd2378","article-title":"The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates","volume":"6","author":"Kramer","year":"2007","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.tiv.2008.11.010_bib17","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1021\/bi00344a031","article-title":"Mechanism of cationic amphiphilic drug inhibition of purified lysosomal phospholipase A1","volume":"24","author":"Kubo","year":"1985","journal-title":"Biochemistry"},{"key":"10.1016\/j.tiv.2008.11.010_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0950-3579(05)80294-8","article-title":"Drug-induced myopathies","volume":"5","author":"Le Quintrec","year":"1991","journal-title":"Bailli\u00e8re\u2019s Clinical Rheumatology"},{"key":"10.1016\/j.tiv.2008.11.010_bib19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00688943","article-title":"Retinal lipidosis in albino rats treated with chlorphentermine and with tricyclic antidepressants","volume":"35","author":"L\u00fcllmann-Rauch","year":"1976","journal-title":"Acta Neuropathology"},{"key":"10.1016\/j.tiv.2008.11.010_bib20","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF01489178","article-title":"Perhexiline induces generalized lipidosis in rats","volume":"56","author":"L\u00fcllmann","year":"1978","journal-title":"Klinische Wochenschrift"},{"key":"10.1016\/j.tiv.2008.11.010_bib21","first-page":"49","article-title":"Drug-induced lysosomal storage disorders","volume":"48","author":"L\u00fcllmann-Rauch","year":"1979","journal-title":"Frontiers of Biology"},{"key":"10.1016\/j.tiv.2008.11.010_bib22","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0041-008X(81)90014-4","article-title":"Tamoxifen-induced generalized lipidosis in rats subchronically treated with high doses","volume":"61","author":"L\u00fcllmann","year":"1981","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.tiv.2008.11.010_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0773.1983.tb01080.x","article-title":"Citalopram-induced generalized lipidosis in rats","volume":"52","author":"L\u00fcllmann-Rauch","year":"1983","journal-title":"Acta Pharmacologica et Toxicological"},{"key":"10.1016\/j.tiv.2008.11.010_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0300-483X(96)03319-7","article-title":"The antimalarials quinacrine and chloroquine induce weak lysosomal storage of sulphated glycosaminoglycans in cell culture and in vivo","volume":"110","author":"L\u00fcllmann-Rauch","year":"1996","journal-title":"Toxicology"},{"key":"10.1016\/j.tiv.2008.11.010_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/17425255.2.5.687","article-title":"In vitro assays and biomarkers for drug-induced phospholipidosis","volume":"2","author":"Monteith","year":"2006","journal-title":"Expert Opinion on Drug Metabolism and Toxicology"},{"key":"10.1016\/j.tiv.2008.11.010_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10565-006-0176-z","article-title":"Validation of an in vitro screen for phospholipidosis using a high-content biology platform","volume":"22","author":"Morelli","year":"2006","journal-title":"Cell Biology and Toxicology"},{"key":"10.1016\/j.tiv.2008.11.010_bib27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/toxsci\/kfm157","article-title":"In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies","volume":"99","author":"Nioi","year":"2007","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.tiv.2008.11.010_bib28","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1021\/ci6004542","article-title":"Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential","volume":"47","author":"Pelletier","year":"2007","journal-title":"Journal of Chemical Information and Modelling"},{"key":"10.1016\/j.tiv.2008.11.010_bib29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0940-2993(04)70180-3","article-title":"Use of physicochemical calculation of pKa and ClogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines","volume":"55","author":"Ploemen","year":"2004","journal-title":"Experimental and Toxicological Pathology"},{"key":"10.1016\/j.tiv.2008.11.010_bib30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/0041-008X(89)90061-6","article-title":"Amiodarone-induced pulmonary toxicity in rats: biochemical and pharmacological characteristics","volume":"97","author":"Reasor","year":"1989","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.tiv.2008.11.010_bib31","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/153537020122600903","article-title":"Drug-induced phospholipidosis: are there functional consequences?","volume":"226","author":"Reasor","year":"2001","journal-title":"Experimental Biology and Medicine (Maywood)"},{"key":"10.1016\/j.tiv.2008.11.010_bib32","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/14740338.5.4.567","article-title":"Drug-induced phospholipidosis: issues and future directions","volume":"5","author":"Reasor","year":"2006","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.tiv.2008.11.010_bib33","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1080\/01926230490431754","article-title":"Epididymal and systemic phospholipidosis in rats and dogs treated with the dopamine D3 selective antagonist PNU-177864","volume":"32","author":"Rudmann","year":"2004","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.tiv.2008.11.010_bib34","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/toxsci\/kfh264","article-title":"A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system","volume":"83","author":"Sawada","year":"2005","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.tiv.2008.11.010_bib35","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.tiv.2006.05.009","article-title":"Improved toxicogenomic screening for drug-induced phospholipidosis using a multiplexed quantitative gene expression ArrayPlate assay","volume":"20","author":"Sawada","year":"2006","journal-title":"Toxicology in Vitro"},{"key":"10.1016\/j.tiv.2008.11.010_bib36","first-page":"355","article-title":"Renal lesions induced by tilorone and an analog. Ultrastructure and acid phosphatase study","volume":"91","author":"Thelmo","year":"1978","journal-title":"The American Journal of Pathology"},{"key":"10.1016\/j.tiv.2008.11.010_bib38","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1001\/jama.298.11.1312","article-title":"Prescribing amiodarone: an evidence-based review of clinical indications","volume":"298","author":"Vassallo","year":"2007","journal-title":"The Journal of the American Medical Association"},{"key":"10.1016\/j.tiv.2008.11.010_bib39","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1080\/01926230490431763","article-title":"Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence","volume":"32","author":"Vonderfecht","year":"2004","journal-title":"Toxicological Pathology"},{"key":"10.1016\/j.tiv.2008.11.010_bib40","first-page":"294","article-title":"Ocular toxicity of hydroxychloroquine","volume":"12","author":"Yam","year":"2006","journal-title":"Hong Kong Medical Journal"}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233308002828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233308002828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T03:40:47Z","timestamp":1738813247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233308002828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0887233308002828"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2008.11.010","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}